deltatrials
Completed PHASE2 Interventional NCT00004641

A Study to Prevent Complications of High Blood Pressure Caused by Hepatitis in Patients With Cirrhosis

Randomized, Double-Blind Study of Timolol (A Nonselective Beta-Adrenergic Blocker) vs Placebo to Prevent Complications of Hepatic Portal Hypertension in Patients With Cirrhosis

Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Conditions Esophageal and Gastric Varices Hypertension, Portal Liver Cirrhosis
Interventions timolol
Updated 1 time since 2017 Last updated: Feb 24, 2000
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Esophageal and Gastric Varices and Hypertension, Portal and is currently completed. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) leads this study, which shows 1 recorded version since 2026 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

~Jan 2017 – present · 114 months · monthly snapshotCompleted

Change History

1 version recorded
Completed — PHASE2 [monthly]

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
  • Yale University
Data source: Office of Rare Diseases (ORD)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations